Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: Mediating influence of the alpha-2A adrenoceptor subtype

Brain Research

Volumn 1246, Issue , 2008, Pages 41-46

  Jentsch, J David ^a   Sanchez, Diana ^a   Elsworth, John D ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenoceptor; Dopamine; Microdialysis; Norepinephrine; Phencyclidine; Prefrontal cortex

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; CLONIDINE; DOPAMINE; GUANFACINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; HISTOPATHOLOGY; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CLONIDINE; DISEASE MODELS, ANIMAL; DOPAMINE; GUANFACINE; IMIDAZOLES; ISOINDOLES; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; SCHIZOPHRENIA;

ANIMALIA; RATTUS;

EID: 57349112971     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.10.006     Document Type: Article

References (48)

1. Arnsten A.F., and Leslie F.M. Behavioral and receptor binding analysis of the alpha 2-adrenergic agonist, 5-bromo-6 [2-imidazoline-2-yl amino] quinoxaline (UK-14304): evidence for cognitive enhancement at an alpha 2-adrenoceptor subtype. Neuropharmacology 30 (1991) 1279-1289
2. Bakshi V.P., and Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J. Pharmacol. Exp. Ther. 283 (1997) 666-674
3. Birnbaum S.G., Podell D.M., and Arnsten A.F. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol. Biochem. Behav. 67 (2000) 397-403
4. Bowers Jr. M.B., and Morton J.B. Diazepam antagonizes effects on dopamine metabolism produced by PCP receptor agonists. Prog. Neuropsychopharmacol. Biol. Psychiatry 16 (1992) 211-215
5. Callado L.F., and Stamford J.A. Alpha2A- but not alpha2B/C-adrenoceptors modulate noradrenaline release in rat locus coeruleus: voltammetric data. Eur. J. Pharmacol. 366 (1999) 35-39
6. Carasso B.S., Bakshi V.P., and Geyer M.A. Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology 37 (1998) 401-404
7. Cartmell J., Monn J.A., and Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 148 (2000) 423-429
8. Coan E.J., and Collingridge G.L. Effects of phencyclidine, SKF 10,047 and related psychotomimetic agents on N-methyl-D-aspartate receptor mediated synaptic responses in rat hippocampal slices. Br. J. Pharmacol. 91 (1987) 547-556
9. Devoto P., Flore G., Pani L., and Gessa G.L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol. Psychiatry 6 (2001) 657-664
10. Galeotti N., Bartolini A., and Ghelardini C. Alpha-2 agonist-induced memory impairment is mediated by the alpha-2A-adrenoceptor subtype. Behav. Brain Res. 153 (2004) 409-417
11. Gerber D.J., and Tonegawa S. Psychotomimetic effects of drugs-a common pathway to schizophrenia?. N. Engl. J. Med. 350 (2004) 1047-1048
12. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
13. Grenhoff J., and Svensson T.H. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur. J. Pharmacol. 165 (1989) 11-18
14. Grenhoff J., Nisell M., Ferre S., Aston-Jones G., and Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. Gen. Sect. 93 (1993) 11-25
15. Harkin A., Morris K., Kelly J.P., O, Donnell J.M., and Leonard B.E. Modulation of MK-801-induced behaviour by noradrenergic agents in mice. Psychopharmacology (Berl) 154 (2001) 177-188
16. Hertel P., Mathe J.M., Nomikos G.G., Iurlo M., Mathe A.A., and Svensson T.H. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 72 (1995) 103-114
17. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
18. Jentsch J.D., and Anzivino L.A. A low dose of the alpha2 agonist clonidine ameliorates the visual attention and spatial working memory deficits produced by phencyclidine administration to rats. Psychopharmacology (Berl) 175 (2004) 76-83
19. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
20. Jentsch J.D., Elsworth J.D., Redmond Jr. D.E., and Roth R.H. Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J. Neurosci. 17 (1997) 1769-1775
21. Jentsch J.D., Dazzi L., Chhatwal J.P., Verrico C.D., and Roth R.H. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci. Lett. 258 (1998) 175-178
22. Jentsch J.D., Tran A., Taylor J.R., and Roth R.H. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology (Berl) 138 (1998) 89-95
23. Jentsch J.D., Wise A., Katz Z., and Roth R.H. Alpha-noradrenergic receptor modulation of the phencyclidine- and delta9-tetrahydrocannabinol-induced increases in dopamine utilization in rat prefrontal cortex. Synapse 28 (1998) 21-26
24. Ji X.H., Ji J.Z., Zhang H., and Li B.M. Stimulation of alpha(2)-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat. Neuropsychopharmacology 33 (2008) 2263-2271
25. Kawahara Y., Kawahara H., and Westerink B.H. Tonic regulation of the activity of noradrenergic neurons in the locus coeruleus of the conscious rat studied by dual-probe microdialysis. Brain Res. 823 (1999) 42-48
26. Kim S.H., Price M.T., Olney J.W., and Farber N.B. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol. Psychiatry 4 (1999) 344-352
27. Klamer D., Palsson E., Fejgin K., Zhang J., Engel J.A., and Svensson L. Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition. Psychopharmacology (Berl) 179 (2005) 479-488
28. Krystal J.H., Anand A., and Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch. Gen. Psychiatry 59 (2002) 663-664
29. Kubota T., Hirota K., Yoshida H., Takahashi S., Anzawa N., Ohkawa H., Kushikata T., and Matsuki A. Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats. Psychopharmacology (Berl) 146 (1999) 335-338
30. Lee A., Wissekerke A.E., Rosin D.L., and Lynch K.R. Localization of alpha2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience 84 (1998) 1085-1096
31. Lorrain D.S., Schaffhauser H., Campbell U.C., Baccei C.S., Correa L.D., Rowe B., Rodriguez D.E., Anderson J.J., Varney M.A., Pinkerton A.B., Vernier J.M., and Bristow L.J. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28 (2003) 1622-1632
32. Marrs W., Kuperman J., Avedian T., Roth R.H., and Jentsch J.D. Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacology 30 (2005) 1500-1510
33. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., and Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309 (1996) 1-11
34. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281 (1998) 1349-1352
35. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 (1997) 2921-2927
36. Murphy B.L., Arnsten A.F., Jentsch J.D., and Roth R.H. Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J. Neurosci. 16 (1996) 7768-7775
37. Pudovkina O.L., Kawahara Y., de Vries J., and Westerink B.H. The release of noradrenaline in the locus coeruleus and prefrontal cortex studied with dual-probe microdialysis. Brain Res. 906 (2001) 38-45
38. Redmond Jr. D.E. Clonidine and the primate locus coeruleus: evidence suggesting anxiolytic and anti-withdrawal effects. Prog. Clin. Biol. Res. 71 (1981) 147-163
39. Robert F., Bert L., Lambas-Senas L., Denoroy L., and Renaud B. In vivo monitoring of extracellular noradrenaline and glutamate from rat brain cortex with 2-min microdialysis sampling using capillary electrophoresis with laser-induced fluorescence detection. J. Neurosci. Methods 70 (1996) 153-162
40. Shi W.X., Pun C.L., Zhang X.X., Jones M.D., and Bunney B.S. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J. Neurosci. 20 (2000) 3504-3511
41. Swanson C.J., and Schoepp D.D. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann. N. Y. Acad. Sci. 1003 (2003) 309-317
42. Tavares A., Handy D.E., Bogdanova N.N., Rosene D.L., and Gavras H. Localization of alpha 2A- and alpha 2B-adrenergic receptor subtypes in brain. Hypertension 27 (1996) 449-455
43. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 165-179
44. Uhlen S., Lindblom J., Tiger G., and Wikberg J.E. Quantification of alpha2A and alpha2C adrenoceptors in the rat striatum and in different regions of the spinal cord. Acta Physiol. Scand. 160 (1997) 407-412
45. Van Gaalen M., Kawahara H., Kawahara Y., and Westerink B.H. The locus coeruleus noradrenergic system in the rat brain studied by dual-probe microdialysis. Brain Res. 763 (1997) 56-62
46. Verma A., and Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16 (1996) 373-379
47. Yonezawa Y., Kuroki T., Kawahara T., Tashiro N., and Uchimura H. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur. J. Pharmacol. 341 (1998) 45-56
48. Young P., Berge J., Chapman H., and Cawthorne M.A. Novel alpha 2-adrenoceptor antagonists show selectivity for alpha 2A- and alpha 2B-adrenoceptor subtypes. Eur. J. Pharmacol. 168 (1989) 381-386